Literature DB >> 27344047

The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review.

Seline van den Ameele1, Linda van Diermen2, Willem Staels3, Violette Coppens2, Glenn Dumont4, Bernard Sabbe2, Manuel Morrens5.   

Abstract

OBJECTIVES: Cytokine level alterations suggest a role for the immune system in the pathophysiology of bipolar disorder (BD). Pharmacotherapy is an important confounding factor in clinical research on cytokine levels. In this systematic review we collate the evidence on blood cytokine levels in medication-free BD and the effects of single mood-stabilizing drugs on these levels.
METHODS: A systematic review was conducted according to the PRISMA statement. We searched the Pubmed and Embase databases for clinical studies reporting either on cytokine levels in medication-free BD or on the effects of single mood-stabilizing drugs on cytokine levels in BD.
RESULTS: Of the 564 articles screened, 17 were included. Fourteen articles report on medication-free patients with BD and indicate state-related cytokine alterations. Six articles discuss the effect of lithium. Whereas no data on short-term effects of lithium were found, ≥2 months lithium use in euthymic populations is associated with normal cytokine levels. Two studies report no effect of valproate and no studies were found on carbamazepine, lamotrigine or antipsychotics. LIMITATIONS: The available studies are characterized by a broad methodological heterogeneity and limited replication between studies.
CONCLUSIONS: This systematic review suggests the presence of state-related cytokine level alterations in medication-free BD with most evidence pointing to a proinflammatory cytokine response in mania. Euthymia and long-term lithium use are associated with normal cytokine levels. To improve our understanding of the impact of mood-stabilizing drugs on cytokine levels, longitudinal studies with medication-free baseline, randomized controlled single-drug treatment protocols and close mood state monitoring are needed.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Cytokines; Inflammation; Lithium; Mood-stabilizing drugs; Systematic review

Mesh:

Substances:

Year:  2016        PMID: 27344047     DOI: 10.1016/j.jad.2016.06.016

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  23 in total

1.  Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.

Authors:  G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-10       Impact factor: 5.270

Review 2.  Targeting the immune system in the treatment of bipolar disorder.

Authors:  Joshua D Rosenblat
Journal:  Psychopharmacology (Berl)       Date:  2019-02-13       Impact factor: 4.530

3.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

4.  Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Levels in Adolescent with Bipolar Disorder and Their Relationship with Metabolic Parameters.

Authors:  Meryem Kasak; Mehmet Fatih Ceylan; Selma Tural Hesapcioglu; Almila Senat; Özcan Erel
Journal:  J Mol Neurosci       Date:  2022-03-23       Impact factor: 3.444

5.  Protein Biomarkers in Monocytes and CD4+ Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry.

Authors:  Keming Gao; Marzieh Ayati; Mehmet Koyuturk; Joseph R Calabrese; Stephen J Ganocy; Nicholas M Kaye; Hillard M Lazarus; Eric Christian; David Kaplan
Journal:  Psychopharmacol Bull       Date:  2022-02-25

Review 6.  Secondary Mania induced by TNF-α inhibitors: A systematic review.

Authors:  Alessandro Miola; Veronica Dal Porto; Nicola Meda; Giulia Perini; Marco Solmi; Fabio Sambataro
Journal:  Psychiatry Clin Neurosci       Date:  2021-11-02       Impact factor: 12.145

7.  Patients with preexisting psychiatric disorders admitted to ICU: a descriptive and retrospective cohort study.

Authors:  Arnaud Gacouin; Adel Maamar; Pierre Fillatre; Emmanuelle Sylvestre; Margaux Dolan; Yves Le Tulzo; Jean Marc Tadié
Journal:  Ann Intensive Care       Date:  2017-01-03       Impact factor: 6.925

8.  The Bipolar Illness Onset study: research protocol for the BIO cohort study.

Authors:  Lars Vedel Kessing; Klaus Munkholm; Maria Faurholt-Jepsen; Kamilla Woznica Miskowiak; Lars Bo Nielsen; Ruth Frikke-Schmidt; Claus Ekstrøm; Ole Winther; Bente Klarlund Pedersen; Henrik Enghusen Poulsen; Roger S McIntyre; Flavio Kapczinski; Wagner F Gattaz; Jakob Bardram; Mads Frost; Oscar Mayora; Gitte Moos Knudsen; Mary Phillips; Maj Vinberg
Journal:  BMJ Open       Date:  2017-06-23       Impact factor: 2.692

Review 9.  Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications.

Authors:  Joshua D Rosenblat; Roger S McIntyre
Journal:  Brain Sci       Date:  2017-10-30

10.  Association between CRP genetic diversity and bipolar disorder comorbid complications.

Authors:  Wahid Boukouaci; José Oliveira; Bruno Etain; Meriem Bennabi; Christina Mariaselvam; Nora Hamdani; Céline Manier; Djaouida Bengoufa; Frank Bellivier; Chantal Henry; Jean-Pierre Kahn; Dominique Charron; Rajagopal Krishnamoorthy; Marion Leboyer; Ryad Tamouza
Journal:  Int J Bipolar Disord       Date:  2018-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.